Lobe Sciences Signs Exclusive Deal For Psilocin Clinical Trials In Australia
Life sciences company Lobe Sciences Ltd.
Meet Blue Serenity, Canada’s First Natural Therapeutic Psilocybin Product For Approved Patients
The Canadian-based company licensed by Health Canada for psychedelic and functional mushrooms production, Optimi Health Corp.
Psychedelic Treatments Vary Greatly By Cost And Setting, What About Efficacy?
Psychedelic therapy is on the rise. June 2022 data from Data Bridge Market Research reports that the US psychedelic drug market could be valued at $9.8 billion by 2029, with a nearly 17% CAGR.
This Psychedelics Company Is Setting Up An Equity Program For Up To $35M In Shares
Cybin Inc. (NEO: CYBN) (NYSE: CYBN) has launched an at-the-market (ATM) equity program through which it will issue and sell up to $35 million in common shares in the company’s capital, from the treasury to the public.
COMPASS Pathways Sued For Alleged Theft Of Psilocybin Trade Secrets
Terran Biosciences Inc. is suing COMPASS Pathways (NASDAQ: CMPS) for the appropriation of trade secrets.
Irwin Naturals: A New Acquisition And The Building Of A National Ketamine-Clinics Chain
The popular herbal supplement producer Irwin Naturals Inc. (OTC: IWINF) has acquired two additional ketamine clinics through the purchase of Invictus Clinics LLC’s assets.
Key Biotech Company Goes All The Way To Reverse Share Split, Here’s What We Know
Psychedelics appear to be here to stay. Yet stocks, shares and finance are another story. On August 4, publicly traded clinical-stage psychedelics firm Mind Medicine Inc.
This Specialized MDMA Producer Will Provide Psychedelics Exclusively For Canadian Massive Research Organization
A new deal has been signed between PharmAla Biotech Holdings Inc. (CSE: MDMA) and InterVivo Solutions for GMP MDMA and engineering MDMA supply towards research on its impact on neuropsychiatric and neurological diseases.